Ovarian cancer cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
Hudakarman (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Cost-effectiveness of therapy== | ==Cost-effectiveness of therapy== | ||
* The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient. | * The [[management]] of [[ovarian cancer]] is composed of [[surgery]] and [[chemotherapy]] that can be either [[adjuvant]] or [[neoadjuvant]] depending on the stage and grade of the [[tumor]] and on the condition and function of the patient. | ||
* Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression <ref name="DuongWright2016">{{cite journal|last1=Duong|first1=M.|last2=Wright|first2=E.|last3=Martin-Nunez|first3=I.|last4=Yin|first4=L.|last5=Ghatage|first5=P.|last6=Fung-Kee-Fung|first6=M.|title=The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada|journal=Current Oncology|volume=23|issue=5|year=2016|pages=461|issn=1718-7729|doi=10.3747/co.23.3139}}</ref> | *[[Bevacizumab]] in addition to [[chemotherapy]] is a [[cost-effective]] alternative for [[ovarian cancer]] patients who are at high risk of progression <ref name="DuongWright2016">{{cite journal|last1=Duong|first1=M.|last2=Wright|first2=E.|last3=Martin-Nunez|first3=I.|last4=Yin|first4=L.|last5=Ghatage|first5=P.|last6=Fung-Kee-Fung|first6=M.|title=The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada|journal=Current Oncology|volume=23|issue=5|year=2016|pages=461|issn=1718-7729|doi=10.3747/co.23.3139}}</ref> | ||
== References == | == References == | ||
Revision as of 20:30, 25 July 2019
|
Ovarian cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian cancer cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Ovarian cancer cost-effectiveness of therapy |
|
Risk calculators and risk factors for Ovarian cancer cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Huda A. Karman, M.D.
Overview
The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient. Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression
Cost-effectiveness of therapy
- The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient.
- Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression [1]
References
- ↑ Duong, M.; Wright, E.; Martin-Nunez, I.; Yin, L.; Ghatage, P.; Fung-Kee-Fung, M. (2016). "The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada". Current Oncology. 23 (5): 461. doi:10.3747/co.23.3139. ISSN 1718-7729.